Progression-free survival in neuroendocrine tumors: Preferred end point, but how should it be defined?

Journal of Clinical Oncology

Volumn 29, Issue 20, 2011, Pages 2835-2836

  Riechelmann, Rachel P ^a   Rego, Juliana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; OCTREOTIDE; PLACEBO; SUNITINIB;

CARCINOID SYNDROME; HUMAN; LETTER; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG EVALUATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; REPRODUCIBILITY OF RESULTS;

EID: 79960284069     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1030     Document Type: Letter

References (6)

1. Kulke MH, Siu LL, Tepper JE, et al: Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934-943, 2011
2. Lebwohl D, Kay A, Berg W, et al: Progression-free survival: Gaining on overall survival as a gold standard and accelerating drug development. Cancer J 15:386-394, 2009
3. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
4. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
5. Yao JC, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT - 2). J Clin Oncol 29 (supp 4; abstr 159), 2011
6. Ambrosini V, Campana D, Bodei L, et al: 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669-673, 2010